IVA
IVA clinical trials: Inventiva S.A.
Every trial on ClinicalTrials.gov where Inventiva S.A. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 6
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
IVA on the catalyst calendar · IVA registry changes
- Primary completion Sep 29, 2026ActualPhase 3NCT04849728A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH)...Inventiva Pharma · NASH - Nonalcoholic SteatohepatitisActive, not recruitingIVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 8, 2024ActualPhase 2NCT05232071Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2...Inventiva Pharma · NASH - Nonalcoholic SteatohepatitisCompletedIVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 20, 2020ActualPhase 2NCT03008070Phase 2b Study in NASH to Assess IVA337Inventiva Pharma · Non-Alcoholic Steatohepatitis (NASH)CompletedIVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 27, 2019ActualPhase 1NCT03866369Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic DoseInventiva Pharma · Healthy SubjectsCompletedIVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 24, 2019ActualPhase 2NCT03370653A Study in MPS VI to Assess Safety and Efficacy of OdiparcilInventiva Pharma · Mucopolysaccharidosis VICompletedIVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2018ActualPhase 2NCT02503644Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic SclerosisInventiva Pharma · Scleroderma, DiffuseCompletedIVALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 18, 2023ActualPhase 2NCT03459079Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver DiseaseUniversity of Florida · Nonalcoholic Fatty Liver Disease (NAFLD)CompletedIVACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2031Sponsor estimateNo phase registeredNCT05651724Global Research Initiative for Patients Screening on MASHJulius Clinical · MASHRecruitingIVACollaboratorNVOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner